0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV60.37%PremiumDec 13, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.57Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet